Gilead’s Descovy gets FDA panel OK for PrEP, but not for womenGilead’s Descovy got a green light from an FDA advisory committee for HIV pre-exposure prophylaxis (PrEP) yesterday – Share XGilead’s Descovy gets FDA panel OK for PrEP, but not for womenhttps://pharmaphorum.com/news/gileads-descovy-gets-fda-panel-ok-for-prep-but-not-for-women/
Allergan says it will shed two drugs as AbbVie takeover loomsAllergan has confirmed that it will divest experimental inflammatory bowel disease therapy brazikumab and marketed drug Zenpep ahead Share XAllergan says it will shed two drugs as AbbVie takeover loomshttps://pharmaphorum.com/news/allergan-says-it-will-shed-two-drugs-as-abbvie-takeover-looms/
Sanofi’s eczema drug gets EU approval to treat adolescentsThe European Commission (EC) has extended the marketing authorisation for Sanofi and Regeneron’s eczema drug Dupixent (dupilumab) to Share XSanofi’s eczema drug gets EU approval to treat adolescentshttps://pharmaphorum.com/news/sanofi-eczema-drug-gets-eu-approval-adolescents/
FDA reviewer backs Gilead’s Descovy for PrEP, but not in womenGilead Sciences’ Descovy, its successor to HIV pre-exposure prophylaxis (PrEP) therapy Truvada, is heading into an FDA advisory Share XFDA reviewer backs Gilead’s Descovy for PrEP, but not in womenhttps://pharmaphorum.com/news/fda-reviewer-backs-gileads-descovy-for-prep-but-not-in-women/
AZ’s Forxiga gets heart claim data on its EU labelAstraZeneca has been cleared to include cardiovascular and kidney outcomes data on the label of its type 2 Share XAZ’s Forxiga gets heart claim data on its EU labelhttps://pharmaphorum.com/news/azs-forxiga-gets-heart-claim-data-on-its-eu-label/
EU clears GSK’s asthma drug Nucala in patient-friendly formatWith competition heating up in the severe asthma category, GlaxoSmithKline has a new EU approval that it hopes Share XEU clears GSK’s asthma drug Nucala in patient-friendly formathttps://pharmaphorum.com/news/eu-clears-gsks-asthma-drug-nucala-in-patient-friendly-format/
NICE backs Bayer’s Xarelto in new stroke and heart attack prevention useBayer’s Xarelto (rivaroxaban) can be funded by the NHS to prevent strokes and heart attacks in high-risk adults Share XNICE backs Bayer’s Xarelto in new stroke and heart attack prevention usehttps://pharmaphorum.com/news/nice-backs-bayers-xarelto-in-new-stroke-and-heart-attack-prevention-use/
Trump’s latest drug price reduction scheme? Import from CanadaThe Trump administration has unveiled its latest plan to cut US spending on medicines, and it rests on Share XTrump’s latest drug price reduction scheme? Import from Canadahttps://pharmaphorum.com/news/trumps-latest-drug-price-reduction-scheme-import-from-canada/
J&J faces FTC probe on Remicade biosimilar defenceJohnson & Johnson’s antibody blockbuster Remicade has proved highly resistant to biosimilar competition – so much so that Share XJ&J faces FTC probe on Remicade biosimilar defencehttps://pharmaphorum.com/news/jj-faces-ftc-probe-on-remicade-biosimilar-defence/
